- LEGN ยท Nasdaq
- Pharmaceutical Preparations
- Somerset, NJ
- 2,900 employees
- CIK 0001801198
Updated from SEC filings through
Top things to know
Executives
-
Ingrid Zhang Chief Executive Officer Form 4, September 16, 2026 -
Alan Bash Interim CEO Form 4, August 18, 2026 - Ying Huang Chief Executive Officer Form 4, July 2, 2026
-
Carlos E. Santos Chief Financial Officer Form 4, September 23, 2026
Legend Biotech Corp is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Somerset, NJ. It trades as LEGN on Nasdaq. Revenue was $627M in the fiscal year ending December 31, 2024, +120.0% from the year before. It reported about 2,900 employees. Ingrid Zhang is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | Not on file | $627M 20-F, 2025-03-11 | $285M 20-F, 2025-03-11 | $117M 20-F, 2025-03-11 | $68.8M 20-F, 2024-03-19 |
| Operating income | -$137M 20-F, 2026-03-10 | -$310M 20-F, 2026-03-10 | -$528M 20-F, 2026-03-10 | Not on file | Not on file |
| SG&A | Not on file | Not on file | Not on file | Not on file | Not on file |
| Net income | -$297M 20-F, 2026-03-10 | -$177M 20-F, 2026-03-10 | -$518M 20-F, 2026-03-10 | -$446M 20-F, 2025-03-11 | -$404M 20-F, 2024-03-19 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| | Chief Executive Officer | Form 4, September 16, 2026 |
| Interim Chief Executive Officer at Legend Biotech | Interim CEO | Form 4, August 18, 2026 |
| Ying Huang | Chief Executive Officer | Form 4, July 2, 2026 |
| Chief Financial Officer | Chief Financial Officer | Form 4, September 23, 2026 |
What Legend Biotech Corp does
We are a global biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications. Our team of approximately 2,900 employees in the United States, China and Europe, our differentiated technology, global development and manufacturing strategy and expertise provide us with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 369.9 million (as of December 31, 2025) | 20-F, March 10, 2026 |
|---|---|---|
| Auditor | Ernst & Young LLP (Iselin, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 17, 2026 | Ingrid Zhang Chief Executive Officer | Buy | 20,000 | $163K | Form 4, November 20, 2026 |
| November 13, 2026 | Peter Salovey Director | Buy | 20,000 | $183K | Form 4, November 16, 2026 |
| September 29, 2026 | Corazon (Corsee) D. Sanders Director | Sale | 27,370 | $259K | Form 4, October 1, 2026 |
| September 21, 2026 | Carlos E. Santos Chief Financial Officer | Sale | 5,430 | $50K | Form 4, September 23, 2026 |
| June 30, 2026 | Patrick John Casey Director | Sale | 6,000 | $89K | Form 4, July 2, 2026 |
| June 25, 2026 | Ying Huang Chief Executive Officer | Sale | 5,566 | $82K | Form 4, June 29, 2026 |
| March 25, 2026 | Ying Huang Chief Executive Officer | Sale | 9,936 | $87K | Form 4, March 27, 2026 |
Recent 8-K events
No 8-K filings on file.
Frequently asked questions about Legend Biotech Corp
- What does Legend Biotech Corp do?
- In its own words, from Item 1 of its 10-K: "We are a global biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications. Our team of approximately 2,900 employees in the United States, China and Europe, our differentiated technology, global development and manufacturing strategy and expertise provide us with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs."
- What is Legend Biotech Corp's revenue?
- $627M for the fiscal year ending December 31, 2024, from its 20-F filed March 11, 2025.
- Is Legend Biotech Corp profitable?
- Legend Biotech Corp reported net income of -$177M for the fiscal year ending December 31, 2024.
- How many employees does Legend Biotech Corp have?
- About 2,900 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Legend Biotech Corp?
- Ingrid Zhang, Chief Executive Officer, as named in a 4 filed September 16, 2026.
- Who is the CFO of Legend Biotech Corp?
- Carlos E. Santos, Chief Financial Officer, as named in a 4 filed September 23, 2026.
- Where is Legend Biotech Corp headquartered?
- Somerset, NJ.
- What is Legend Biotech Corp's stock ticker?
- LEGN on Nasdaq.
- What industry is Legend Biotech Corp in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Legend Biotech Corp's website?
- legendbiotech.com.
- When does Legend Biotech Corp report earnings next?
- February 10, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Legend Biotech Corp a public company?
- Yes. Legend Biotech Corp files with the SEC under CIK 0001801198 and trades as LEGN.
- Who audits Legend Biotech Corp?
- Ernst & Young LLP, Iselin, New Jersey, as named in its latest annual report (10-K).
- How many shares of Legend Biotech Corp are outstanding?
- 369.9 million shares as of December 31, 2025, from its 20-F filed March 10, 2026.
- Have Legend Biotech Corp insiders traded stock recently?
- Since March 25, 2026, officers and directors reported 5 open-market sales worth about $567K and 2 purchases worth about $346K on Forms 4 and 5. The most recent: Ingrid Zhang (Chief Executive Officer) bought 20,000 shares on November 17, 2026.